Nitrofurantoin 100 mg BID for Uncomplicated Cystitis
Yes, nitrofurantoin 100 mg twice daily is an appropriate and guideline-recommended first-line treatment for uncomplicated cystitis in women.
Recommended Dosing and Duration
Nitrofurantoin monohydrate/macrocrystals 100 mg twice daily for 5 days is the preferred regimen 1. The IDSA/ESMID guidelines give this a strong recommendation (A-I evidence level) based on:
- Clinical cure rates of 90-93% at early follow-up 1
- Microbiological cure rates of 86-92% 1
- Late clinical cure rates of 84% at 28-30 days 1
The 5-day regimen is equivalent to 3 days of trimethoprim-sulfamethoxazole in both clinical and microbiological outcomes 2. A 7-day course (100 mg BID) is also acceptable and shows similar efficacy (93% clinical cure, 86% bacterial cure) 1.
Why Nitrofurantoin is First-Line
The guidelines prioritize nitrofurantoin because it offers:
- Minimal antimicrobial resistance - resistance rates remain exceptionally low despite decades of use 1, 3, 4
- Minimal collateral damage - achieves high urinary concentrations with minimal serum/tissue levels, preserving gut and other microbiomes 1, 3
- Fluoroquinolone-sparing - reserves broader-spectrum agents for more serious infections 1, 2
Comparative Efficacy
Recent high-quality evidence demonstrates nitrofurantoin's superiority over alternatives:
- vs. Fosfomycin: A 2018 RCT showed 5-day nitrofurantoin achieved 70% clinical resolution vs. 58% for single-dose fosfomycin (12% absolute difference, p=0.004), with microbiologic resolution of 74% vs. 63% (p=0.04) 5
- vs. TMP-SMX: Equivalent efficacy when TMP-SMX resistance is <20%, but nitrofurantoin avoids resistance concerns 1, 2
Important Caveats and Contraindications
Renal function matters: Nitrofurantoin efficacy decreases with declining kidney function. For every 10 mL/min decrease in eGFR, clinical failure increases (aOR 1.05) 6.
- eGFR ≥60 mL/min: Nitrofurantoin is superior to fosfomycin (14.6% vs. 20.7% failure rate) 6
- eGFR <60 mL/min: Consider fosfomycin instead (nitrofurantoin failure rate increases to 23.3% vs. 16.0% for fosfomycin) 6
Do not use for:
- Pyelonephritis (inadequate tissue concentrations)
- CrCl <30 mL/min (traditional cutoff, though some data suggest <60 mL/min is more appropriate)
- Pregnancy at term (risk of hemolytic anemia in newborn)
Safety Profile
Common adverse effects include nausea and headache (28-34% in trials) 1. Serious but rare complications include:
- Pulmonary reactions: Chronic pulmonary fibrosis with prolonged use (>6 months) - monitor for dyspnea, cough 7
- Peripheral neuropathy: Risk increases with renal impairment, diabetes, anemia, vitamin B deficiency 7
- Hepatotoxicity: Rare but can be severe 7
These risks are primarily associated with long-term prophylactic use, not short 5-7 day treatment courses.
Clinical Algorithm
For uncomplicated cystitis in women:
Check renal function if available
- eGFR ≥60: Use nitrofurantoin 100 mg BID × 5 days
- eGFR <60: Consider fosfomycin 3g single dose instead
If local TMP-SMX resistance <20%: TMP-SMX is an alternative (160/800 mg BID × 3 days) 1
Reserve fluoroquinolones for complicated infections or pyelonephritis 1
The 2024 EAU guidelines and 2024 WikiGuidelines consensus statement continue to endorse nitrofurantoin as first-line therapy 8, 9, confirming its sustained role despite evolving resistance patterns globally.